Condition: Hypoparathyroidism · Endocrine System Diseases · Parathyroid Diseases · Sponsor: Ascendis Pharma Bone Diseases A/S
This trial has a duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.
This description comes directly from the study's public registry record.
Ascendis Registry Inquiries · +4561161658 · asnd_registryinquiries@ascendispharma.com
Always discuss trial participation with your own doctor first.
| Ascendis Pharma Investigational Site | Reno, Nevada, United States | Recruiting |
| Ascendis Pharma Investigational Site | New York, New York, United States | Recruiting |
| Ascendis Pharma Investigational Site | Spokane Valley, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07081997